Skip to search formSkip to main contentSkip to account menu

Hu1D 10

Known as: Hu1D10 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

apolizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.
Apolizumab is a humanized monoclonal antibody against a polymorhic epitope on HLA DRs, which demonstrated evidence for… 
2004
2004
Hu 1 D 10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
The 1D10 antigen is the target for Hu1D10 (apolizumab), a humanized HLA-DR -chain–specific antibody that is currently in clinical… 
2003
2003
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002
Novel approaches have been designed to treat leukemia based on our understanding of the genetic and biochemical lesions present… 
2002
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)